Elizaveta V Benevolenskaya (Elizaveta Benevolenskaya)

Publication Activity (10 Years)

Years Active: 2018-2022
Publications (10 Years): 5

Top Topics

Angiotensin Converting Enzyme

Top Venues

Nature communications

Proceedings of the National Academy of Sciences of the United States of America

Cell death & disease

This page only lists publications with an associated author ORCID identifier.

Publications

Daniel R Principe, Alexandre Ferro Aissa, Sandeep Kumar, Thao N D Pham, Patrick W Underwood, Rakesh Sathish Nair, Rong Ke, Basabi Rana, Jose G Trevino, Hidayatullah G Munshi, Elizaveta V Benevolenskaya, Ajay Rana
Calcium channel blockers potentiate gemcitabine chemotherapy in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America 119 (18) (2022)
Vaibhav Chand, Xiubei Liao, Grace Guzman, Elizaveta V Benevolenskaya, Pradip Raychaudhuri
Hepatocellular carcinoma evades RB1-induced senescence by activating the FOXM1-FOXO1 axis. Oncogene 41 (30) (2022)
Alexandre Ferro Aissa, Abul Bashar Mir Md Khademul Islam, Majd M Ariss, Cammille C Go, Alexandra E Rader, Ryan D Conrardy, Alexa M Gajda, Carlota Rubio-Perez, Klara Valyi-Nagy, Mary Pasquinelli, Lawrence E Feldman, Stefan J Green, Nuria Lopez-Bigas, Maxim V Frolov, Elizaveta V Benevolenskaya
Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer. Nature communications 12 (1) (2021)
Menglin Liu, Lianghui Zhang, Glenn Marsboom, Ankit Jambusaria, Shiqin Xiong, Peter T Toth, Elizaveta V Benevolenskaya, Jalees Rehman, Asrar B Malik
Sox17 is required for endothelial regeneration following inflammation-induced vascular injury. Nature communications 10 (1) (2019)
Marianna Halasi, Ben Hitchinson, Binal N Shah, Renáta Váraljai, Irum Khan, Elizaveta V Benevolenskaya, Vadim Gaponenko, Jack L Arbiser, Andrei L Gartel
Honokiol is a FOXM1 antagonist. Cell death & disease 9 (2) (2018)